| First Author | Erickson LD | Year | 2002 |
| Journal | J Clin Invest | Volume | 109 |
| Issue | 5 | Pages | 613-20 |
| PubMed ID | 11877469 | Mgi Jnum | J:75346 |
| Mgi Id | MGI:2176360 | Doi | 10.1172/JCI14110 |
| Citation | Erickson LD, et al. (2002) Short-circuiting long-lived humoral immunity by the heightened engagement of CD40. J Clin Invest 109(5):613-20 |
| abstractText | Agonistic alpha CD40 Ab's have been shown to be potent immune adjuvants for both cell- and humoral-mediated immunity. While enhancing short-lived humoral immunity, the administration of a CD40 agonist during thymus-dependent immune responses ablates germinal center formation, prematurely terminates the humoral immune response, blocks the generation of B cell memory, and prevents the generation of long-lived bone marrow plasma cells. Interestingly, some of these effects of heightened CD40 engagement could be mimicked by enhancing the magnitude of antigen-specific T cell help. Taken together, these studies demonstrate that as the magnitude of CD40 signaling intensifies, the fate of antigen-reactive B cells can be dramatically altered. These are the first studies to describe the multifaceted function of CD40 in determining the fate of antigen-reactive B cells and provide novel insights into how CD40 agonists can short-circuit humoral immunity. |
